Local
Amgen, In A Buy Zone, Unveils Highly Anticipated Novartis-Rivaling Sjogren's Data
Meet in Common connects news with real conversations. Use ThinkMatch to arrange a Roundtable and meet people to discuss this story.
Source: Investor's Business Daily

Amgen unveiled test results Wednesday that suggest it could have one of the first immune-modulating treatments for Sjogren's disease.
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at Investor's Business Daily


